A national, multicentre, randomised, controlled, parallel-arms, phase III clinical trial of neoadjuvant FOLFOXIRI and chemoradiotherapy versus neoadjuvant CAPOX/FOLFOX and chemoradiotherapy in patients with high-risk locally advanced rectal cancer: study protocol of the MEND-IT II trial.
Banken E, Borg M, van Hellemond IEG, van Ravensteijn SG, Peulen HMU, Verrijssen AE, Nederend J, Daniels-Gooszen AW, van Oudheusden TR, van Lijnschoten G, Bloemen JG, Rutten HJT, van Westreenen HL, de Groot JWB, Verhoef C, Tanis PJ, Grotenhuis BA, Aalbers AGJ, Werter IM, Hartogh MDD, Douma JAJ, Calon TGA, Iersel LBJV, Beets GL, Tuynman JB, Intven MPW, van Kuijk SMJ, Berbée M, Buffart TE, Roodhart JML, Burger JWA; Dutch Colorectal Cancer Group.
Banken E, et al. Among authors: de groot jwb.
BMC Cancer. 2026 May 18. doi: 10.1186/s12885-026-16072-5. Online ahead of print.
BMC Cancer. 2026.
PMID: 42151882